David Green, MD
Pulmonary Disease · Shreveport, LANPI 1902874704
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 827 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by GSK at 26.5% of the total.
Across 827 payments — averaging $19.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$4K
- AstraZeneca$3K
- Actelion Pharmaceuticals US, Inc.$2K
- Boehringer Ingelheim$777
- Insmed, Inc.$526
- Sanofi$521
- plus $4K from 22 others
Across 121 payments — averaging $16,696 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$1.3M
- AstraZeneca$278K
- Eli Lilly$267K
- GSK$129K
- Sanofi$70K
What the payments were for
- Food & beverage$15,52498%
- Education$3822%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 265 | $4,208 |
| AstraZeneca(2 entities) | 130 | $3,276 |
| Actelion Pharmaceuticals US, Inc. | 168 | $2,484 |
| Boehringer Ingelheim | 42 | $777 |
| Insmed, Inc. | 26 | $526 |
| Sanofi | 18 | $521 |
| Grifols USA, LLC | 19 | $455 |
| Merck | 19 | $421 |
| United Therapeutics Corporation | 16 | $354 |
| Shionogi Inc | 5 | $287 |
| Amgen | 10 | $280 |
| Paratek Pharmaceuticals, Inc. | 7 | $259 |
| Genentech USA, Inc. | 14 | $219 |
| Johnson & Johnson(2 entities) | 14 | $218 |
| Regeneron Healthcare Solutions, Inc. | 10 | $210 |
| La Jolla Pharmaceutical Company | 5 | $192 |
| Mylan Specialty L.p. | 10 | $189 |
| Mallinckrodt Hospital Products Inc. | 8 | $177 |
| Bayer | 9 | $173 |
| Advanced Respiratory, Inc | 10 | $167 |
| Gilead | 2 | $146 |
| Baxter Healthcare | 6 | $113 |
| Verona Pharma, Inc. | 4 | $79 |
| Teva Pharmaceuticals USA, Inc. | 5 | $67 |
| Novartis | 2 | $42 |
| Boston Scientific | 1 | $27 |
| Viatris Specialty LLC | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,907 in reported general payments places this provider in the 85th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 518 | $446,082 |
| OfevNintedanib Esylate | 30 | $387,763 |
| OpsumitMacitentan | 22 | $271,213 |
| AdempasRiociguat | 13 | $183,140 |
| Breo ElliptaFluticasone/Vilanterol | 97 | $58,179 |
| Dupixent PenDupilumab | 14 | $54,842 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 47 | $38,821 |
| Spiriva RespimatTiotropium Bromide | 21 | $28,694 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 39 | $20,688 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 29 | $20,279 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 25 | $18,993 |
| SymbicortBudesonide/Formoterol Fumarate | 48 | $16,065 |
| EliquisApixaban | 22 | $15,094 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 452 | $12,657 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 61 | $10,278 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $4,208 | $538,426694 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $777 | $455,729105 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $2,484 | $271,21322 claims |
| BayerAdempas | $173 | $183,14013 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,276 | $54,88695 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 189 pulmonary disease providers in Louisiana.
Other pulmonary disease in Shreveport
- Robert HolladayShreveport$22K
- Scott HowardShreveport$20K
- Himanshu DesaiShreveport$16K
- David ChambersShreveport$13K
- Ahmed ViraniShreveport$12K
- Ashley FerraroShreveport$10K
- Andrea EspinozaHouma$655K
- Joseph LaskyNew Orleans$447K
- Hollis O NealBaton Rouge$418K
- Ramsy AbdelghaniNew Orleans$308K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.